Unnamed: 0,title,date,stock,sentiment
283998.0,"Corcept Therapeutics Q1 EPS $0.340 Beats $0.220 Estimate, Sales $93.200M Beat $87.010M Estimate",2020-05-04 16:18:00-04:00,CORT,neutral
283999.0,"Corcept Therapeutics Q1 Adj. EPS $0.340 Beats $0.220 Estimate, Sales $93.200M Beat $87.010M Estimate",2020-05-04 16:14:00-04:00,CORT,neutral
284000.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,CORT,neutral
284001.0,"Cantor Fitzgerald Reiterates Neutral on Corcept Therapeutics, Raises Price Target to $15",2020-02-21 06:45:00-05:00,CORT,neutral
284002.0,17 Stocks Moving In Thursday's After-Hours Session,2020-02-20 17:33:00-05:00,CORT,neutral
284003.0,Corcept Therapeutics shares are trading higher after the company reported better-than-expected Q4 sales results. The company also reaffirmed FY20 sales guidance.,2020-02-20 16:26:00-05:00,CORT,positive
284004.0,Corcept Reaffirms FY20 Sales Guidance $355M-$375M,2020-02-20 16:19:00-05:00,CORT,neutral
284005.0,"Corcept Therapeutics Q4 EPS $0.24 Misses $0.25 Estimate, Sales $87.9M Beat $87.67M Estimate",2020-02-20 16:19:00-05:00,CORT,negative
284006.0,"Corcept Therapeutics Wins IPR Patent Trial, PTAB Rules Neptune Generics Failed To Prove '348 Korlym Patent Claims Were Valid",2020-02-10 13:23:00-05:00,CORT,positive
284007.0,Corcept Therapeutics Q4 Sales $87.9M Up From $66.831M YoY,2020-01-30 16:15:00-05:00,CORT,neutral
284008.0,63 Biggest Movers From Yesterday,2019-11-21 04:49:00-05:00,CORT,neutral
284009.0,"Corcept Therapeutics Shares Resume Trade, Down 29.3%",2019-11-20 15:25:00-05:00,CORT,positive
284010.0,Corcept Therapeutics Shares Expected To Resume Trade At 3:24:23 p.m. EST,2019-11-20 15:22:00-05:00,CORT,positive
284011.0,"Corcept Therapeutics Shares Halted On Circuit Breaker, Down 15.6% For Session",2019-11-20 15:18:00-05:00,CORT,positive
284012.0,"Corcept Therapeutics Shares Fall As Hearing Teva Patent Trial Against Co.'s '214 Korlym Has Been Instituted By Patent Trial, Appeal Board As Patent Claims Determined to Be Likely Invalid",2019-11-20 15:16:00-05:00,CORT,positive
284013.0,Corcept Therapeutics Narrows FY19 Sales Guidance $300M-$315M,2019-11-07 17:35:00-05:00,CORT,neutral
284014.0,"Corcept Therapeutics Q3 EPS $0.31 Beats $0.2 Estimate, Sales $81.505M Beat $78M Estimate",2019-11-07 17:35:00-05:00,CORT,neutral
284015.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,CORT,negative
284016.0,"Benzinga's Top Upgrades, Downgrades For September 24, 2019",2019-09-24 09:46:00-04:00,CORT,positive
284017.0,"Jefferies Initiates Coverage On Corcept Therapeutics with Buy Rating, Announces $20 Price Target",2019-09-24 06:37:00-04:00,CORT,neutral
284018.0,"Benzinga's Top Upgrades, Downgrades For September 6, 2019",2019-09-06 09:37:00-04:00,CORT,positive
284019.0,"H.C. Wainwright Initiates Coverage On Corcept Therapeutics with Buy Rating, Announces $18 Price Target",2019-09-06 07:27:00-04:00,CORT,neutral
284020.0,Corcept Therapeutics Announces Allowance Of Additional Patent Covering The Use Of Korlym To Treat Patients With Cushing's Syndrome,2019-08-28 16:10:00-04:00,CORT,positive
284021.0,"Hearing Corcept Therapeutics Has Received EU Orphan Drug Designation, Unconfirmed",2019-08-21 10:42:00-04:00,CORT,negative
284022.0,82 Biggest Movers From Friday,2019-08-05 05:40:00-04:00,CORT,neutral
284023.0,60 Stocks Moving In Friday's Mid-Day Session,2019-08-02 13:43:00-04:00,CORT,neutral
284024.0,"Corcept Therapeutics Q2 EPS $0.25 Beats $0.18 Estimate, Sales $72.257M Beat $70.88M Estimate",2019-08-01 17:01:00-04:00,CORT,neutral
284025.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,CORT,negative
284026.0,"Corcept Therapeutics 8-K Shows Co. Received Paragraph IV Notice Letter Advising Sun Pharma Submitted Abbreviated New Drug Application For FDA Authorization To Manufacture, Use Or Sell Generic Version Of KORLYM, 300mg In US",2019-06-11 16:10:00-04:00,CORT,neutral
284027.0,The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace,2019-06-01 11:37:00-04:00,CORT,neutral
284028.0,'$CORT Corcept Therapeutics gets European Commission approval of Relacorilant for the treatment of Cushing's Syndrome.' -Tweets TradeHawk,2019-05-29 13:52:00-04:00,CORT,positive
284029.0,Corcept Therapeutics To Present Data From Phase 1/2 Trial Of Relacorilant Plus Nab-Paclitaxel In Patients With Solid Tumors At The American Society Of Clinical Oncology Annual Meeting,2019-05-28 08:06:00-04:00,CORT,positive
284030.0,Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%,2019-05-10 13:09:00-04:00,CORT,positive
284031.0,Corcept Therapeutics Reaffirms FY2019 Sales Guidance from $285M-315M to $285M-315M,2019-05-09 16:49:00-04:00,CORT,neutral
284032.0,"Corcept Therapeutics Q1 EPS $0.2 Beats $0.19 Estimate, Sales $64.8M Miss $69.29M Estimate",2019-05-09 16:48:00-04:00,CORT,negative
284033.0,"The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",2019-05-09 07:56:00-04:00,CORT,neutral
284034.0,Corcept Therapeutics Reports EMA Recommended Orphan Drug Designation For Relacorilant To Treat Patients With Cushing's Syndrome,2019-05-02 18:41:00-04:00,CORT,positive
284035.0,Corcept Therapeutics Announces European Medicines Agency Recommended Orphan Drug Designation For Relacorilant To Treat Patients With Cushing's Syndrome,2019-05-02 18:40:00-04:00,CORT,positive
284036.0,"Corcept Therapeutics Q4 EPS $0.24 Beats $0.17 Estimate, Sales $66.831M Miss $69.32M Estimate",2019-02-25 17:03:00-05:00,CORT,negative
284037.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,CORT,neutral
284038.0,Hearing Corcept Therapeutics Lost IPR Patent Case For '348 Korlym Patent By Neptune Genetics; Unconfirmed,2019-02-15 15:48:00-05:00,CORT,negative
284039.0,Corcept's Korlym Patent Added To The FDA Orange Book,2019-02-07 15:36:00-05:00,CORT,neutral
284040.0,Blue Orca Announces Corcept Therapeutics Short,2019-02-05 10:33:00-05:00,CORT,neutral
284041.0,60 Biggest Movers From Friday,2019-02-04 05:05:00-05:00,CORT,neutral
284042.0,45 Stocks Moving In Friday's Mid-Day Session,2019-02-01 12:34:00-05:00,CORT,neutral
284043.0,10 Biggest Price Target Changes For Friday,2019-02-01 09:41:00-05:00,CORT,neutral
284044.0,"The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of  Titan's Opioid Disorder Treatment Implant",2019-02-01 09:10:00-05:00,CORT,positive
284045.0,Corcept shares are trading lower after the company said Q4 revenue will be worse than analysts expected.,2019-02-01 08:48:00-05:00,CORT,negative
284046.0,35 Stocks Moving In Friday's Pre-Market Session,2019-02-01 08:33:00-05:00,CORT,neutral
284047.0,"Cantor Fitzgerald Downgrades Corcept Therapeutics to Neutral, Lowers Price Target to $14",2019-02-01 07:56:00-05:00,CORT,negative
284048.0,Corcept Therapeutics Prelim. Q4 Sales $66.8M Up From $53.28M YoY,2019-01-31 16:13:00-05:00,CORT,neutral
284049.0,24 Stocks Moving In Tuesday's Pre-Market Session,2019-01-29 08:09:00-05:00,CORT,neutral
284050.0,55 Biggest Movers From Friday,2019-01-28 05:40:00-05:00,CORT,neutral
284051.0,UPDATE: Negative Call On Corcept Coming Out Of Roddy Boyd's SIRF 'Corcept Therapeutics: The Company That Perfectly Explains the Health Care Crisis',2019-01-25 12:16:00-05:00,CORT,negative
284052.0,Corcept Therapeutics Shares Fall 8% As Traders Circulate Word Of A Negative Call From Unnamed Source,2019-01-25 12:12:00-05:00,CORT,negative
284053.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2018-12-30 15:27:00-05:00,CORT,neutral
284054.0,The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results,2018-12-23 10:37:00-05:00,CORT,neutral
284055.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Thurs., Dec. 13, 2018",2018-12-13 15:11:00-05:00,CORT,positive
284056.0,Corcept Therapeutics Reports Allowance Of Added Patent Covering Use Of Korlym To Treat Patients With Cushing's Syndrome,2018-12-13 08:35:00-05:00,CORT,positive
284057.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Wed., Dec. 12, 2018",2018-12-12 12:49:00-05:00,CORT,positive
284058.0,41 Stocks Moving In Wednesday's Mid-Day Session,2018-12-12 12:33:00-05:00,CORT,neutral
284059.0,"B. Riley FBR Sees Corcept Therapeutics Final Patent Issuance In Coming Weeks, Expects Patent To Protect Korlym Through 2037; Reiterates Buy, $22 Price Target",2018-12-12 10:26:00-05:00,CORT,positive
284060.0,10 Biggest Price Target Changes For Wednesday,2018-12-12 09:40:00-05:00,CORT,neutral
284061.0,"Benzinga's Top Upgrades, Downgrades For December 12, 2018",2018-12-12 09:28:00-05:00,CORT,positive
284062.0,"Concerpt Therapeutics shares are continuing higher after receiving a patent for Krlym, which will give the company power over generic drug makers.",2018-12-12 08:57:00-05:00,CORT,positive
284063.0,"Cantor Fitzgerald Upgrades Corcept Therapeutics to Overweight, Raises Price Target to $29",2018-12-12 08:09:00-05:00,CORT,negative
284064.0,Hearing Cantor Fitzgerald Upgraded Corcept Therapeutics To Overweight With A $29 Price Target; Unconfirmed,2018-12-12 06:25:00-05:00,CORT,negative
284065.0,48 Biggest Movers From Yesterday,2018-12-12 05:14:00-05:00,CORT,neutral
284066.0,Corcept Therapeutics Shares Spike ~18% Over Last Few Mins.; Traders Attributing Move To Vague Word Of Patent Approval,2018-12-11 14:13:00-05:00,CORT,positive
284067.0,Corcept Therapeutics Announces First Patient Dosed In Phase 3 Trial Of Relacorilant To Treat Patients With Cushing's Syndrome,2018-11-19 09:05:00-05:00,CORT,positive
284068.0,"Corcept Therapeutics Q3 Adj. EPS $0.22 Beats $0.17 Estimate, Sales $64.4M Miss $67.41M Estimate",2018-11-01 16:56:00-04:00,CORT,negative
284069.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,CORT,negative
284070.0,"Stocks Which Set New 52-Week Low Friday, October 26th",2018-10-29 09:56:00-04:00,CORT,negative
284071.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,CORT,negative
284072.0,"Stocks Which Set New 52-Week Low Yesterday, October 23rd",2018-10-24 10:06:00-04:00,CORT,negative
284073.0,Judge Denies Teva Pharmaceuticals' Motion To Dismiss Corcept Therapeutics' Allegations Of Patent Infringement,2018-10-24 08:15:00-04:00,CORT,negative
284074.0,Corcept Therapeutics Shares Up 4% Over Last Few Mins. As Traders Circulate Court Order Doc Showing Teva Motion To Dismiss Co. Complaint Related To Generic Product Was Denied,2018-10-23 15:03:00-04:00,CORT,negative
284075.0,Corcept Therapeutics shares are ticking lower amid reports Teva has received tentative FDA approval for Mifepristone,2018-10-18 15:09:00-04:00,CORT,positive
284076.0,"FDA Site Shows Orphan Drug Designation For Corcept Therapeutics' Relacorilant In The Treatment Of Endogenous Cushing Syndrome, Dated Oct. 15",2018-10-16 10:06:00-04:00,CORT,neutral
284077.0,Corcept Therapeutics Reports Received Orphan Drug Designation For Relacorilant As Treatment For Pancreatic Cancer,2018-10-01 07:15:00-04:00,CORT,negative
284078.0,"Insider Buys Of The Week: Andeavor, Corcept, Portola",2018-08-25 18:01:00-04:00,CORT,neutral
284079.0,"Cantor Fitzgerald Initiates Coverage On Corcept Therapeutics with Neutral Rating, Announces $17 Price Target",2018-08-23 07:08:00-04:00,CORT,neutral
284080.0,61 Biggest Movers From Friday,2018-08-13 06:43:00-04:00,CORT,neutral
284081.0,60 Stocks Moving In Friday's Mid-Day Session,2018-08-10 13:27:00-04:00,CORT,neutral
284082.0,Corcept Therapeutics shares are trading 10.7% lower following the company's quarterly earnings report. Earnings per share and sales both fell below analysts' estimates.,2018-08-10 11:23:00-04:00,CORT,positive
284083.0,30 Stocks Moving In Friday's Pre-Market Session,2018-08-10 08:32:00-04:00,CORT,neutral
284084.0,"The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss",2018-08-10 07:38:00-04:00,CORT,negative
284085.0,7 Stocks Moving In Thursday's After-Hours Session,2018-08-09 18:22:00-04:00,CORT,neutral
284086.0,"Corcept Therapeutics Q2 EPS $0.20 Misses $0.24 Estimate, Sales $62.312M Miss $68.5M Estimate",2018-08-09 16:12:00-04:00,CORT,negative
284087.0,Corcept Therapeutics Option Alert: Aug 17 $12 Puts Sweep (36) near the Ask: 947 @ $0.301 vs 26 OI; Earnings 7/31 After Close [est] Ref=$16.49,2018-06-21 12:29:00-04:00,CORT,positive
284088.0,60 Biggest Movers From Yesterday,2018-06-19 04:02:00-04:00,CORT,neutral
284089.0,Corcept Therapeutics Option Alert: Aug 17 $17 Puts Sweep (26) near the Ask: 600 @ $1.101 vs 708 OI; Earnings 7/31 After Close [est] Ref=$18.31,2018-06-18 13:53:00-04:00,CORT,positive
284090.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,CORT,negative
284091.0,Corcept Therapeutics Shares Down 5.7% After Sitfel Earlier Downgraded To Hold; Firm Said Stock Is 'Fairly Valued',2018-05-31 14:42:00-04:00,CORT,positive
284092.0,"Corcept Therapeutics Is 'Fairly Valued,' Stifel Says In Downgrade",2018-05-31 12:52:00-04:00,CORT,neutral
284093.0,"Benzinga's Top Upgrades, Downgrades For May 31, 2018",2018-05-31 09:23:00-04:00,CORT,positive
284094.0,Stifel Nicolaus Downgrades Corcept Therapeutics to Hold,2018-05-31 07:20:00-04:00,CORT,neutral
284095.0,"UPDATE: FDA Offers Guidelines, Background For Reference Listed Drug Access Inquiries, Related To Claim Of Blocking Generic Rivals",2018-05-17 12:38:00-04:00,CORT,negative
284096.0,"FDA Commissioner Scot Gottlieb Highlights List Of Cos. Which Have Potentially Blocked Access To Samples Of Their Branded Products: Pfizer, Biogen, INSYS, VIVUS, Valeant, Corcept Therapeutics",2018-05-17 09:57:00-04:00,CORT,negative
284097.0,"Corcept Therapeutics Q1 EPS $0.19 Beats $0.16 Estimate, Sales $57.7M Miss $58.82M Estimate",2018-05-08 17:15:00-04:00,CORT,negative
284098.0,24 Stocks Moving In Monday's Pre-Market Session,2018-04-23 08:02:00-04:00,CORT,neutral
284099.0,Corcept Therapeutics Files Lawsuit Against Teva Pharmaceuticals for Infringement of Korlym Patents,2018-03-15 17:00:00-04:00,CORT,negative
284100.0,"B. Riley Initiates Coverage On Corcept Therapeutics with Buy Rating, Announces $30.00 Price Target",2018-03-09 08:32:00-05:00,CORT,neutral
284101.0,"Corcept Therapeutics Reports Q4 GAAP EPS $0.77 vs $0.04 In Same Qtr. Last Year, Sales $55.3M vs $53.7M Est.",2018-02-22 16:47:00-05:00,CORT,neutral
284102.0,33 Biggest Movers From Yesterday,2018-02-06 05:09:00-05:00,CORT,neutral
284103.0,31 Stocks Moving In Monday's Mid-Day Session,2018-02-05 12:43:00-05:00,CORT,neutral
284104.0,Mid-Day Market Update: Dow Falls Over 250 Points; Enphase Energy Shares Spike Higher,2018-02-05 12:21:00-05:00,CORT,positive
284105.0,Mid-Morning Market Update: Markets Open Lower; Bristol-Myers Profit Tops Expectations,2018-02-05 10:13:00-05:00,CORT,positive
284106.0,Corcept Therapetics Option Alert: Aug 17 $26 Calls Sweep (13) at the Bid: 611 @ $4.101 vs 25 OI; Earnings 4/30 After Close [est] Ref=$24.11,2018-02-02 11:26:00-05:00,CORT,positive
284107.0,44 Biggest Movers From Yesterday,2018-02-02 04:43:00-05:00,CORT,neutral
284108.0,38 Stocks Moving In Thursday's Mid-Day Session,2018-02-01 12:25:00-05:00,CORT,neutral
284109.0,Corcept Therapeutics Reports Prelim. Q4 Sales $53.3M vs $53.9M Est.; FY17 Sales $159.2M vs $159.8M Est.,2018-02-01 08:37:00-05:00,CORT,neutral
284110.0,"Jim Cramer Gives His Opinion On Alphabet, Switch, And More",2017-12-22 07:21:00-05:00,CORT,neutral
284111.0,38 Biggest Movers From Yesterday,2017-12-22 05:50:00-05:00,CORT,neutral
284112.0,"Corcept Therapeutics Shares Up 13.8% On More Than 2x Avg. Volume, Watch For Shares To Test Near-Term Resistance Around $18.50 Level",2017-12-21 12:25:00-05:00,CORT,positive
284113.0,36 Stocks Moving In Thursday's Mid-Day Session,2017-12-21 12:17:00-05:00,CORT,neutral
284114.0,S&P Dow Jones Indices Announces 'Interactive Brokers Group Set to Join S&P MidCap 400; Alarm.com Holdings and Corcept Therapeutics to Join S&P SmallCap 600',2017-12-20 17:21:00-05:00,CORT,positive
284115.0,31 Stocks Moving In Monday's Pre-Market Session,2017-12-18 08:12:00-05:00,CORT,neutral
284116.0,2 Reasons Why Cantor Fitzgerald Is Bullish on Strongbridge Biopharma,2017-12-06 12:40:00-05:00,CORT,neutral
284117.0,"Corcept Therapeutics Reports Q3 EPS $0.11 vs $0.14 Est., Sales $42.8M vs $42.03M Est.",2017-11-02 17:39:00-04:00,CORT,neutral
284118.0,"Weakness In Corcept Shares Is 'Overdone,' According To Analyst",2017-10-10 16:01:00-04:00,CORT,negative
284119.0,Corcept Shares Tick Slightly Higher Over Last Min. As Hearing Stifel Out Defending Against Downside,2017-10-10 13:01:00-04:00,CORT,positive
284120.0,Corcept Therapeutics Shares Have Moved 6.8% Lower Within 10 Minutes,2017-10-10 11:43:00-04:00,CORT,neutral
284121.0,Mid-Morning Market Update: Markets Open Higher; Wal-Mart Reports $20B Buyback Plan,2017-10-10 10:14:00-04:00,CORT,neutral
284122.0,"Stifel Nicolaus Initiates Coverage On Corcept Therapeutics with Buy Rating, Announces $20.00 Price Target",2017-08-31 06:54:00-04:00,CORT,neutral
284123.0,"UPDATE: Corcept Says 'does not believe termination of the Dohmen
Agreement will materially affect its operations or financial results for
2017 or beyond'",2017-08-30 09:08:00-04:00,CORT,positive
284124.0,"UPDATE: Corcept Therapeutics Says 'Immediately following Dohmen's cessation of services under the Dohmen Agreement, Corcept began serving Korlym (R) patients through another specialty pharmacy, Optime Care'",2017-08-30 09:07:00-04:00,CORT,positive
284125.0,UPDATE: Corcept Filed Motion To Dismiss Dohmen Complaint,2017-08-30 09:06:00-04:00,CORT,negative
284126.0,"8-K From Corcept Therapeutics Shows Co. Filed Complaint Against Dohmen In Delaware Court, Alleging 'fraudulent inducement, negligent misrepresentation, breach of contract, breach of the covenant of good faith and fair dealing and conversion...'",2017-08-30 09:06:00-04:00,CORT,negative
284127.0,"Jim Cramer Gives His Opinion On First Solar, Apache And More",2017-08-29 07:26:00-04:00,CORT,neutral
284128.0,18 Biggest Mid-Day Gainers For Wednesday,2017-08-02 12:21:00-04:00,CORT,neutral
284129.0,"Corcept Therapeutics Reports Q2 EPS $0.13 vs. $0.07 Est., Sales $35.6M vs. $32.53M Est.",2017-08-01 16:57:00-04:00,CORT,neutral
284130.0,"Corcept Therapeutics Reports Q1 Adj. EPS $0.06 vs $0.03 Est., Sales $27.6M vs $25.53M Est.",2017-05-01 16:29:00-04:00,CORT,neutral
284131.0,Concept Therapeutics Files For $200M Mixed Shelf Offering,2017-03-13 16:52:00-04:00,CORT,neutral
284132.0,UPDATE: Corcept Raises FY17 Sales Outlook from $115M-$125M to $120M-$130M vs $121.4M Est.,2017-03-06 08:32:00-05:00,CORT,neutral
284133.0,Corcept Raises FY17 Sales Outlook,2017-03-06 08:31:00-05:00,CORT,neutral
284134.0,"Corcept Therapeutics Reports Q4 Adj. Net Income $6.9M vs $3.1M in Same Qtr. Last Year, GAAP EPS $0.04 vs $0.01 YoY, Sales $23.8M, Inline",2017-03-06 08:31:00-05:00,CORT,neutral
284135.0,"Ladenburg On Biotech: Starts Achillion, Alnylam, Corcept, Trevana At Buy",2017-02-02 09:21:00-05:00,CORT,neutral
284136.0,"Ladenburg Thalmann Initiates Coverage On Corcept Therapeutics At Buy, Announces $14 Price Target",2017-02-02 07:59:00-05:00,CORT,neutral
284137.0,"Ladenburg Thalmann Initiates Coverage On Corcept Therapeutics at Buy, Announces $14.00 Target",2017-02-02 07:27:00-05:00,CORT,neutral
284138.0,UPDATE: Corcept Sees FY17 Sales $115M-$125M vs $124M Est.,2017-01-30 16:11:00-05:00,CORT,neutral
284139.0,UPDATE: Corcept Reports Prelim. FY16 Sales $81.3M vs $81M Est.,2017-01-30 16:11:00-05:00,CORT,neutral
284140.0,"UPDATE: Corcept Reports Prelim. Q4 GAAP EPS $0.04, Sales $23.8M vs $23.5M Est.",2017-01-30 16:10:00-05:00,CORT,neutral
284141.0,"Corcept Therapeutics Reports Prelim Q4, FY16 Results; Offers FY17 Outlook",2017-01-30 16:10:00-05:00,CORT,neutral
284142.0,Corcept Therapeutics Expected To Hold Guidance Call This Morning,2017-01-30 06:46:00-05:00,CORT,neutral
284143.0,"Corcept Therapeutics Says Will Offer Prelim. FY16, FY17 Guidance on Jan. 30",2017-01-23 16:08:00-05:00,CORT,neutral
284144.0,Mid-Day Market Update: Conatus Jumps Following Announcement of Licensing Deal With Novartis; Sucampo Shares Slide,2016-12-20 12:04:00-05:00,CORT,positive
284145.0,Corcept Therapeutics Announces Encouraging Results of Phase 1/2 Trial of Mifepristone Plus Eribulin in Triple-Negative Breast Cancer at 2016 San Antonio Breast Cancer Symposium,2016-12-10 20:01:00-05:00,CORT,negative
284146.0,San Antonio Breast Cancer Symposium (SABCS) Continues Today,2016-12-07 08:37:00-05:00,CORT,negative
284147.0,"Corcept Therapeutics Reports Q3 non-GAAP EPS $0.04, GAAP EPS $0.02 vs $0.01 Est, Revenue $21.7M vs $21.24M Est",2016-11-01 16:49:00-04:00,CORT,neutral
284148.0,"Corcept Therapeutics Reports Q2 EPS $0.03 vs. Est. $0.01, Rev. $19.7M vs. Est. $18.36M",2016-08-02 17:41:00-04:00,CORT,neutral
284149.0,UPDATE: Corcept Says 'First patient enrolled in Phase 1/2 trial of selective cortisol modulator CORT125134 plus nab-paclitaxel (Celgene's Abraxane®) to treat a range of solid-tumor cancers',2016-06-02 16:09:00-04:00,CORT,positive
284150.0,UPDATE: Corcept Says 'Preliminary efficacy results in Phase 1/2 trial of mifepristone plus eribulin (Eisai's Halaven®) to treat TNBC indicate combination is active; final results expected in mid-'16',2016-06-02 16:08:00-04:00,CORT,positive
284151.0,Corcept Offers Update on Progress in Cortisol Modulation Oncology Program,2016-06-02 16:08:00-04:00,CORT,positive
284152.0,"Corcept Therapeutics Reports Q1 $0.02 Vs Est $0.01, Sales $16.061M Vs Est $16.32M",2016-05-03 17:48:00-04:00,CORT,neutral
284153.0,Corcept Therapeutics Releases Promising Pre-Clincal Data And Has Begun Recruiting Patients For Phase 1/2 Trial Of CORT125134,2016-04-28 16:40:00-04:00,CORT,positive
284154.0,Corcept Therapeutics Reaffirms FY16 Sales Outlook of $76M-$81M vs $78.6M Est.,2016-03-01 16:11:00-05:00,CORT,neutral
284155.0,"Corcept Therapeutics Reports Q4 GAAP EPS $0.01 vs $(0.01) Est., Sales $15M vs $17.2M Est.",2016-03-01 16:10:00-05:00,CORT,neutral
284156.0,"Corcept Therapeutics Sees FY 2015 GAAP EPS $(0.06) Vs Est $(0.09), Revs $50.3M Vs Est $50.94M",2016-01-28 16:15:00-05:00,CORT,neutral
284158.0,"Corcept Therapeutics Says Will Give Prelim. FY15, FY16 Outlook on Jan. 28, '16",2016-01-21 16:10:00-05:00,CORT,neutral
284159.0,Mid-Morning Market Update: Markets Edge Lower; Cal-Maine Misses Q2 Expectations,2015-12-24 10:08:00-05:00,CORT,negative
284160.0,Corcept Therapeutics Reports First Efficacy Results in Phase 1/2 Trial of Mifepristone in Combination With Eribulin for the Treatment of Patients With Metastatic Triple-Negative Breast Cancer,2015-12-14 08:31:00-05:00,CORT,negative
284161.0,"Corcept Therapeutics Reports Q3 EPS $(0.01) vs $(0.02) Est., Sales $13.3M vs $14M Est.; Sees FY15 Sales $49M-$53M vs $52.1M Est.",2015-11-05 18:37:00-05:00,CORT,neutral
284162.0,UPDATE: Corcept Therapeutics to Commence Separation of Phase 2 Trials of CORT125134 in Q1'16,2015-10-13 16:08:00-04:00,CORT,neutral
284163.0,Results of Phase 1 Trial of Next-Generation Cortisol Modulator CORT125134 to Be Presented at Annual Meeting of the American Association of Pharmaceutical Scientists,2015-10-13 16:05:00-04:00,CORT,neutral
284164.0,Corcept Therapeutics Names Dr. Robert Fishman Chief Medical Officer,2015-09-28 08:30:00-04:00,CORT,neutral
284165.0,Option Alert: Cortis Therapeutics Aug $6 Call; 564 Contracts vs 536 OI; Now $5.41,2015-08-18 14:12:00-04:00,CORT,positive
284166.0,"Corcept Therapeutics Reports Q2 EPS $(0.02) vs. Est. $(0.04), Rev. $12M vs. Est. $11.67M",2015-08-05 17:10:00-04:00,CORT,neutral
284167.0,Mid-Day Market Update: Dow Dips Over 1%; Harley-Davidson Shares Rise On Earnings Beat,2015-07-21 12:46:00-04:00,CORT,positive
284168.0,"Corec ept Reports Q1 Loss $0.05 Vs Est Loss $0.04, Sales $10.1M Vs Est $10.51M",2015-05-07 16:22:00-04:00,CORT,negative
284169.0,Benzinga's Top Initiations,2015-04-21 09:36:00-04:00,CORT,positive
284170.0,"FBR Capital Initiates Coverage on Corcept Therapeutics at Outperform, Announces $12.00 PT",2015-04-21 06:06:00-04:00,CORT,neutral
284171.0,Warrant Exercises Generate $17.2M; Proceeds to Advance Next-Generation Compounds and Support Commercialization of Korlym,2015-04-01 16:07:00-04:00,CORT,positive
284172.0,5 NASDAQ Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years,2015-03-30 09:28:00-04:00,CORT,positive
284173.0,"Piper Jaffray Upgrades Corcept Therapeutics to Overweight, Raises PT to $9.00",2015-03-11 06:22:00-04:00,CORT,negative
284174.0,Corcept Therapeutics Reports Q4 Adj. Loss of $0.02/Share vs Loss of $0.06/Share Est.,2015-03-04 16:08:00-05:00,CORT,negative
284175.0,Corcept Therapeutics Incorporated Cuts FY2014 Sales To $25.0M-27.0M,2014-11-04 16:28:00-05:00,CORT,negative
284176.0,Corcept Therapeutics Incorporated Sees FY2014 Sales $25.0M-29.0M,2014-08-05 16:30:00-04:00,CORT,neutral
284177.0,Corcept Therapeutics Incorporated Reports Q2 EPS of $(0.05) vs $(0.10) Est; Revenue of $5.85M vs $6.0M Est,2014-08-05 16:30:00-04:00,CORT,neutral
284178.0,"Corcept Therapeutics Director Baker Jr Buys 103,386 Shares @$2.32/Share -Form 4",2014-06-12 14:39:00-04:00,CORT,positive
284179.0,Morning Market Losers ,2014-05-07 09:48:00-04:00,CORT,negative
284180.0,"Corcept Therapeutics Resumes Trading Down 50% Following Earnings Miss, Trial Halt",2014-05-07 09:04:00-04:00,CORT,negative
284181.0,Shares of Corcept to Resume Trade at 9AM EDT,2014-05-07 08:37:00-04:00,CORT,positive
284182.0,From Corcept Earnings Press Release: Shows Mifepristone Trial Has Failed to Show Efficacy,2014-05-07 08:37:00-04:00,CORT,negative
284183.0,Corcept Therapeutics Incorporated Reports Q1 EPS of $(0.11) vs $(0.09) Est; Product Revenue of $4.40M vs $5.01M Est,2014-05-07 08:30:00-04:00,CORT,neutral
284184.0,Corcept Therapeutics Shares Halted News Pending,2014-05-07 08:25:00-04:00,CORT,positive
284185.0,"Option Alert: Corcept Therapeutics May $4 Call; 2,546 Contracts Traded vs 1,836 OI; Currently $3.82",2014-04-17 15:44:00-04:00,CORT,positive
284186.0,"Brinson Patrick Initiates Coverage on Corcept Therapeutics Incorporated at Market Outperform, Announces $8.00 PT",2014-04-01 09:17:00-04:00,CORT,neutral
284187.0,UPDATE: Stifel Terminates Coverage on Corcept Therapeutics Due to Reallocation of Resources,2014-03-10 09:40:00-04:00,CORT,neutral
284188.0,"UPDATE: Stifel Downgrades Corcept Therapeutics, See Gradual Progress with Korlym",2014-01-13 08:13:00-05:00,CORT,positive
284189.0,"Stifel Nicolaus Downgrades Corcept Therapeutics Incorporated to Hold, Removes $3.00 PT",2014-01-13 07:21:00-05:00,CORT,neutral
284190.0,Corcept Therapeutics Incorporated Reports Q3 EPS of $(0.08) vs $(0.12) Est,2013-11-07 16:40:00-05:00,CORT,neutral
284191.0,"Janney Capital Downgrades Corcept Therapeutics to Neutral, Lowers PT to $2.00",2013-08-09 07:53:00-04:00,CORT,negative
284192.0,"Credit Suisse Downgrades Corcept Therapeutics Incorporated to Neutral, Lowers PT to $2.00",2013-08-09 07:22:00-04:00,CORT,positive
284193.0,Corcept Therapeutics Incorporated Reports Q2 EPS of $(0.10) vs $(0.11) Est; Revenue of $1.89M vs $2.72M Est,2013-08-08 16:26:00-04:00,CORT,neutral
284194.0,UPDATE: Piper Jaffray Downgrades Corcept Therapeutics to Neutral Following 1Q13 Earnings Report,2013-05-06 09:46:00-04:00,CORT,neutral
284195.0,"Piper Jaffray Downgrades Corcept Therapeutics Incorporated to Neutral, Lowers PT to $2.00",2013-05-06 06:35:00-04:00,CORT,negative
284196.0,Corcept Therapeutics Incorporated Reports Q1 EPS of $(0.10) vs $(0.09) Est,2013-05-02 16:51:00-04:00,CORT,neutral
284197.0,"Corcept Therapeutics Incorporated Reports Q4 EPS of $(0.09), Inline",2013-03-07 17:03:00-05:00,CORT,neutral
284198.0,"Janney Capital Initiates Coverage on Corcept Therapeutics Incorporated at Buy, Announces $3.00 PT",2013-01-02 17:04:00-05:00,CORT,neutral
284199.0,From Earlier: Cowen & Company Downgrades Corcept Therapeutics Incorporated to Neutral,2012-12-10 11:59:00-05:00,CORT,neutral
284200.0,"Credit Suisse Reinstates Coverage on Corcept Therapeutics at Outperform, Lowers PT from $6 to $4",2012-11-13 07:39:00-05:00,CORT,positive
284201.0,UPDATE: Piper Jaffray Downgrades Corcept Therapeutics to Underweight on Competitive Concerns  ,2012-11-08 07:56:00-05:00,CORT,positive
284202.0,"Piper Jaffray Downgrades Corcept Therapeutics from Neutral to Underweight, Lowers PT from $3 to $1.10",2012-11-08 05:55:00-05:00,CORT,negative
284203.0,UPDATE: Oppenheimer Downgrades Corcept Therapeutics to Perform on Disappointing Sales  ,2012-11-02 14:45:00-04:00,CORT,negative
284204.0,Oppenheimer Downgraded Corcept Therapeutics from Outperform to Market Perform,2012-11-02 09:50:00-04:00,CORT,neutral
284205.0,"Bank of America Maintains Corcept Therapeutics at Underperform, Lowers PO from $4 to $2",2012-11-01 08:37:00-04:00,CORT,negative
284206.0,Corcept Therapeutics Appoints Daniel M. Bradbury to Board of Directors ,2012-10-15 09:03:00-04:00,CORT,neutral
284207.0,UPDATE: Piper Jaffray Downgrades Corcept Therapeutics to Neutral on Korlym Outlook  ,2012-09-13 11:33:00-04:00,CORT,neutral
284208.0,"Piper Jaffray Downgrades Corcept Therapeutics from Overweight to Neutral, Lowers PT from $5 to $3",2012-09-13 05:46:00-04:00,CORT,negative
284209.0,"Oppenheimer Maintains Corcept Therapeutics at Outperform, Raises PT from $6 to $7",2012-08-07 16:22:00-04:00,CORT,neutral
284210.0,Corcept Therapeutics Reports Q2 EPS $-0.09 vs $-0.11 Est,2012-08-07 08:44:00-04:00,CORT,neutral
284211.0,Corcept Therapeutics Halted for News,2012-08-07 08:25:00-04:00,CORT,neutral
284212.0,UPDATE: Oppenheimer Lowers PT on Corcept Therapeutics from $9 to $8,2012-07-24 09:03:00-04:00,CORT,negative
284213.0,"Oppenheimer Maintains Corcept Therapeutics at Outperform, Lowers PT from $9 to $8",2012-07-24 07:31:00-04:00,CORT,negative
284214.0,"Equity Moves on Sell-Side Sentiment for July 13, 2012",2012-07-13 15:11:00-04:00,CORT,neutral
284215.0,UPDATE: Bank of America Initiates Corcept Therapeutics at Underperform on Korlym Launch Caution  ,2012-07-13 08:37:00-04:00,CORT,neutral
284216.0,"Bank of America Initiates Coverage on Corcept Therapeutics at Underperform, Announces PO of $4",2012-07-13 05:53:00-04:00,CORT,negative
284217.0,Corcept Therapeutics Announces Underwritten Public Offering of 11M Shares ,2012-07-02 09:23:00-04:00,CORT,positive
284218.0,Corcept Therapeutics Commences Public Offering of 11M Shares ,2012-07-02 07:25:00-04:00,CORT,positive
284219.0,ThinkEquity Initiates Coverage On Corcept Therapeutics at Buy,2012-06-29 06:46:00-04:00,CORT,neutral
284220.0,Ladenburg Thalmann: Corcept Therapeutics SEISMIC Article,2012-04-10 09:33:00-04:00,CORT,neutral
284221.0,Corcept Therapeutics Says Data Shows Clinical Improvement,2012-04-09 12:47:00-04:00,CORT,positive
284222.0,Corcept Therapeutics Trading 2% Higher on Heavy Volume; Currently at $4.04,2012-04-09 12:46:00-04:00,CORT,neutral
284223.0,Corcept Says Investors Exercised Warrants to Buy 4.2M Shares,2012-03-26 09:05:00-04:00,CORT,positive
284224.0,Corcept Therapeutics Announces Exercise of Warrants and Private Placement of New Warrants  ,2012-03-26 09:01:00-04:00,CORT,neutral
284225.0,"Corcept to Introduce Korlym by May 1st, 2012",2012-03-05 09:03:00-05:00,CORT,neutral
284226.0,Corcept Therapeutics: One and Done or More to Come?,2012-02-22 04:04:00-05:00,CORT,neutral
284227.0,Corcept Analyst: US Sales of Cushing Syndrome Drug Korlym Could Reach $200M/Year,2012-02-21 12:34:00-05:00,CORT,neutral
284228.0,UPDATE: Stifel Nicolaus Increases Target to $9 on Concept Therepeutics,2012-02-21 09:37:00-05:00,CORT,neutral
284229.0,Corcept Therapeutics Pops 61% After Friday's FDA Approval,2012-02-21 09:13:00-05:00,CORT,positive
284230.0,"Stifel Nicolaus Maintains Corcept Therapeutics at Buy, Raises PT from $7 to $9",2012-02-21 08:08:00-05:00,CORT,neutral
284231.0,Corcept Therapeutics Rises 60% on Friday's FDA Approval for Korlym,2012-02-21 07:50:00-05:00,CORT,positive
284232.0,PREVIEW: Corcept Therapeutics to Resume Trading at 6:40pm,2012-02-17 18:30:00-05:00,CORT,neutral
284233.0,Corcept Therapeutics Receives FDA Approval for Korlym,2012-02-17 16:41:00-05:00,CORT,positive
284234.0,Corcept Therapeutics Halted; Wins FDA Approval on its Korlym Drug ,2012-02-17 16:13:00-05:00,CORT,positive
284235.0,Reminder: Corcept Therapeutics Has Their PDUFA Date Tomorrow,2012-02-16 08:07:00-05:00,CORT,neutral
284236.0,Notable Call Options Activity in Corcept Therapeutics,2012-01-31 14:09:00-05:00,CORT,neutral
284237.0,Will Korlym Relieve Your Portfolio's Stress?,2012-01-16 23:56:00-05:00,CORT,negative
284238.0,Notable Put Options Activity in Corcept Therapeutics,2012-01-05 12:42:00-05:00,CORT,neutral
284239.0,Corcept's FDA Submission Will Not Require a Risk Evaluation and Mitigation Strategy,2011-12-15 09:01:00-05:00,CORT,positive
284240.0,Oppenheimer Names Corcept Therapeutics on December's Top Ideas ,2011-11-28 10:27:00-05:00,CORT,positive
284241.0,"Ladenburg Thalmann Maintains Buy, PT on Corcept Therapeutics",2011-11-10 08:13:00-05:00,CORT,neutral
284242.0,Oppenheimer Maintains Outperform Rating on Corcept Therapeutics,2011-09-26 07:31:00-04:00,CORT,neutral
284243.0,Corcept Announces No FDA Advisory Committee Meeting Planned in Connection With New Drug Application for CORLUX for Cushing's Syndrome  ,2011-08-22 09:04:00-04:00,CORT,negative
284244.0,Gary C. Robb Joins Corcept as Chief Financial Officer  ,2011-08-22 09:00:00-04:00,CORT,neutral
284245.0,"McNicoll, Lewis & Vlak Reiterates Corcept Therapeutics Buy, $8 PT",2011-08-09 15:42:00-04:00,CORT,neutral
284246.0,UPDATE: Oppenheimer Initiates Coverage on Corcept Technologies,2011-08-05 09:34:00-04:00,CORT,neutral
284247.0,"Oppenheimer Initiates Corcept Therapeutics At Outperform, $8 PT",2011-08-05 08:37:00-04:00,CORT,neutral
284248.0,FDA Accepts Submission of New Drug Application for CORLUX for Cushing's Syndrome ,2011-06-30 08:00:00-04:00,CORT,positive
284249.0,Piper Jaffray Raises PT On Corcept Therapeutics To $7,2011-06-07 07:41:00-04:00,CORT,neutral
284250.0,UPDATE: Piper Jaffray Raises PT on Corcept Therapeutics to $7,2011-06-06 08:46:00-04:00,CORT,neutral
284251.0,Piper Jaffray Raises PT On Corcept Therapeutics To $7,2011-06-06 07:02:00-04:00,CORT,neutral
284252.0,Corcept Therapeutics Announces NDA Submitted to the FDA for the Use of CORLUX in Cushing's Syndrome  ,2011-04-15 16:06:00-04:00,CORT,neutral
284253.0,Global Hunter Comments On Corcept's Corlux NDA Submission During Week Of April 11,2011-04-01 08:56:00-04:00,CORT,neutral
284254.0,Piper Jaffray Comments On Corlux NDA Announcement (CORT),2011-04-01 07:27:00-04:00,CORT,neutral
284255.0,Corcept Therapeutics Announces NDA Submission to Be Completed the Week of April 11 ,2011-03-31 16:29:00-04:00,CORT,neutral
284256.0,Piper Jaffray Reduces Corcept Therapeutics PT From $7.40 (CORT),2011-03-10 09:23:00-05:00,CORT,neutral
284257.0,Piper Jaffray Remains OW On Corcept Therapeutics Following Corlux Data,2011-01-11 07:49:00-05:00,CORT,neutral
284258.0,Corcept Therapeutics Slightly Up After FDA News (CORT),2010-12-22 09:57:00-05:00,CORT,neutral
284259.0,Corcept Therapeutics Hormone Drug Meets Main Trial Goal (CORT),2010-12-22 08:07:00-05:00,CORT,neutral
284260.0,Biotech Calendar: Key Dates for December,2010-11-30 07:00:00-05:00,CORT,neutral
284261.0,"Stocks That Created New 52-Week Highs (AKRX, AMMD, ATRO, CSTR, CORT)",2010-05-05 13:19:00-04:00,CORT,positive
284262.0,CORT Initiated With Outperform At JMP Securities,2010-05-04 07:26:00-04:00,CORT,positive
